OrbiMed Capital GP III LLC
CIK 1432241 · last filed 2018-05-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$90.26M
Companies
9
Total Filings
23
Lifetime Open-Market Net
-$326.29M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Director | 56,389 | $13.60 | $766.9K | -$8.57M | 2 | 2018-05-02 |
| GKOS | Director | 159,798 | $182.00 | $29.08M | -$83.18M | 3 | 2018-03-06 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 796,311 | — | — | $13.74M | 2 | 2017-08-25 |
| ViewRay, Inc. (VRAY) Delisted | Director | 86,107 | $0.03 | $2.2K | $10.07M | 1 | 2016-08-24 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 12,193 | $0.88 | $10.7K | $23.10M | 1 | 2016-06-29 |
| Sientra, Inc. (SIEN) Delisted | 10%+ Owner | 1,710 | $0.17 | $298 | -$18.13M | 4 | 2015-10-13 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | 10%+ Owner | 7,424 | $0.54 | $4.0K | $16.27M | 1 | 2013-05-22 |
| AMRN | Director | 285 | $14.01 | $4.0K | -$287.49M | 7 | 2012-09-05 |
| PCRX | 10%+ Owner | 2,509,100 | $24.38 | $61.17M | $7.91M | 2 | 2012-03-13 |
Recent Filings · Page 2 of 3
23 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-07-08 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Buy (P) | +1,500,000 | $4.12M | EDGAR |
| 2015-06-30 | GKOS | Mixed | +8,693,811 | -$633.6K | EDGAR |
| 2014-07-24 | Roka BioScience, Inc. (ROKA) Delisted | Mixed | +9,647,091 | $13.80M | EDGAR |
| 2013-05-22 | AMBIT BIOSCIENCES CORP (AMBI) Delisted | Mixed | +4,369,980 | $16.27M | EDGAR |
| 2012-09-05 | AMRN | Sell (S) | −701,100 | -$10.12M | EDGAR |
| 2012-07-30 | AMRN | Sell (S) | −1,098,900 | -$16.05M | EDGAR |
| 2012-03-13 | PCRX | Sell (S) | −300,300 | -$3.34M | EDGAR |
| 2011-05-03 | AMRN | Sell (S) | −398,700 | -$6.41M | EDGAR |
| 2011-04-26 | AMRN | Sell (S) | −2,400,000 | -$37.90M | EDGAR |
| 2011-04-25 | AMRN | Sell (S) | −2,250,000 | -$37.50M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.